Literature DB >> 27102649

Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs.

Elizabeth Braunlin1, Raymond Wang2.   

Abstract

The growing availability of innovative treatments for rare genetic diseases with a cardiac component-such as the mucopolysaccharidoses (MPSs)-has changed these syndromes from 'back of the textbook' curiosities of childhood to chronic, but rare, adult cardiac conditions that require both centres of expertise and knowledgeable subspecialists. The MPSs are inherited progressive lysosomal storage diseases, occurring in about 1:25 000 births and resulting from absence of functional hydrolases responsible for the degradation of glycosaminoglycans, naturally occurring complex sugars ubiquitous throughout the body. In the heart, accumulation of glycosaminoglycans occurs within the cardiac valves, the epicardial coronary arteries, the myocytes and cardiac interstitium and the walls of the great vessels. As a consequence, cardiac valve regurgitation and stenosis, diffuse coronary artery stenosis, myocardial dysfunction and aortic root dilation often occur. Haematopoietic cell transplantation and enzyme replacement therapy have changed the previously lethal natural history of the MPSs to one of survival well into adulthood. Despite this improved lifespan, the left-sided cardiac valves continue to show progressive functional involvement and cardiac valve replacement is not uncommon, especially in adults. The risk of any intervention is increased in these patients because of the systemic effects of the disease on the respiratory system and cervical cord. Our current understanding of other cardiac issues in adults with the MPSs, especially with the coronary circulation and myocardium, is meagre and more needs to be known to effectively care for this emerging population of adults. Incorporation of the MPSs, as well as other now-treatable rare diseases, into the educational curriculum of current and future adult subspecialists is an important next step. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2016        PMID: 27102649     DOI: 10.1136/heartjnl-2015-309258

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

1.  Natural history of echocardiographic abnormalities in mucopolysaccharidosis III.

Authors:  Carolyn M Wilhelm; Kristen V Truxal; Kim L McBride; John P Kovalchin; Kevin M Flanigan
Journal:  Mol Genet Metab       Date:  2018-04-27       Impact factor: 4.797

2.  Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.

Authors:  Alia Ahmed; Kyle Rudser; Kelly E King; Julie B Eisengart; Paul J Orchard; Elsa Shapiro; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2022-03-10       Impact factor: 4.204

3.  The Carotid Intima-Media Thickness and Arterial Stiffness of Pediatric Mucopolysaccharidosis Patients Are Increased Compared to Both Pediatric and Adult Controls.

Authors:  Raymond Y Wang; Kyle D Rudser; Donald R Dengel; Elizabeth A Braunlin; Julia Steinberger; David R Jacobs; Alan R Sinaiko; Aaron S Kelly
Journal:  Int J Mol Sci       Date:  2017-03-15       Impact factor: 5.923

Review 4.  Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III.

Authors:  Hsiang-Yu Lin; Ming-Ren Chen; Shan-Miao Lin; Chung-Lieh Hung; Dau-Ming Niu; Tung-Ming Chang; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

5.  Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases.

Authors:  Maria Paola Belfiore; Francesca Iacobellis; Emma Acampora; Martina Caiazza; Marta Rubino; Emanuele Monda; Maria Rosaria Magaldi; Antonietta Tarallo; Marcella Sasso; Valeria De Pasquale; Roberto Grassi; Salvatore Cappabianca; Paolo Calabrò; Simona Fecarotta; Salvatore Esposito; Giovanni Esposito; Antonio Pisani; Luigi Michele Pavone; Giancarlo Parenti; Giuseppe Limongelli
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

6.  Progression of Cardiovascular Manifestations in Adults and Children With Mucopolysaccharidoses With and Without Enzyme Replacement Therapy.

Authors:  Fabiano de Oliveira Poswar; Hallana Souza Santos; Angela Barreto Santiago Santos; Solano Vinicius Berger; Carolina Fischinger Moura de Souza; Roberto Giugliani; Guilherme Baldo
Journal:  Front Cardiovasc Med       Date:  2022-01-12

7.  The factors affecting lipid profile in adult patients with Mucopolysaccharidosis.

Authors:  Karolina M Stepien; Fiona J Stewart; Chris J Hendriksz
Journal:  Mol Genet Metab Rep       Date:  2017-05-18

Review 8.  Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses.

Authors:  Miriam Rigoldi; Elena Verrecchia; Raffaele Manna; Maria Teresa Mascia
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

Review 9.  Mucopolysaccharidosis Type I.

Authors:  Francyne Kubaski; Fabiano de Oliveira Poswar; Kristiane Michelin-Tirelli; Ursula da Silveira Matte; Dafne D Horovitz; Anneliese Lopes Barth; Guilherme Baldo; Filippo Vairo; Roberto Giugliani
Journal:  Diagnostics (Basel)       Date:  2020-03-16

10.  Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II.

Authors:  Hsiang-Yu Lin; Ming-Ren Chen; Chung-Lin Lee; Shan-Miao Lin; Chung-Lieh Hung; Dau-Ming Niu; Tung-Ming Chang; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2021-02-23       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.